Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Am J Obstet Gynecol. 2011 Jun 15;205(3):249.e1–249.e8. doi: 10.1016/j.ajog.2011.06.024

Table 2.

Intranasal Vaccine Administration Titers

Serum C5a-IgG 4 weeks (n) 8 weeks (n) 11 weeks (n) 40 weeks (n)
75:25 10ug 100000 (29) 100000 (29) 100000 (26) 100 (10)
75:25 30ug 100000 (28) 100000 (27) 100000 (25) 100 (4)
50:50 30ug 100000 (29) 100000 (28) 100000 (27) 1000 (4)
Serum C5a-IgA
75:25 10ug 10000 (29) 100000 (29) 10000 (26) 100000 (10)
75:25 30ug 100000 (28) 100000 (27) 10000 (25) 100000 (4)
50:50 30ug 0 (29) 100000 (28) 10000 (27) 0 (4)
Vaginal C5a-IgG
75:25 10ug 10000 (29) 100000 (29) 100000 (26) 10000 (10)
75:25 30ug 100000 (28) 100000 (27) 100000 (25) 0 (4)
50:50 30ug 10000 (29) 100000 (28) 100000 (27) 10000 (4)
Vaginal C5a-IgA
75:25 10ug 0 (29) 100000 (29) 10000 (26) 10000 (10)
75:25 30ug 100000 (28) 100000 (27) 10000 (25) 0 (4)
50:50 30ug 0 (29) 100000 (28) 10000 (27) 100 (4)

Titers are shown as 1:Y (Y represents the dilution). A Student’s t-test was used to determine the significant titer. The largest dilution tested that was significantly different from mice receiving 75:25 0ug is the reported titer.